Working… Menu

The Effect of a Nutritional Supplement Product Containing Cactus Fruit Juice (Nopalea) on C-Reactive Protein (NOPALEA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01881178
Recruitment Status : Completed
First Posted : June 19, 2013
Last Update Posted : December 30, 2014
Information provided by (Responsible Party):
Mark Mattie, University of Bridgeport

Brief Summary:
This study has been developed to investigate the anti-inflammatory effects of a commercial product (Nopalea) containing Prickly Pear Cactus Fruit Juice in healthy adults. The research method employs a double blind, placebo controlled, and time-series (repeat measures) design with high-sensitivity C-Reactive Protein (HS-CRP) serving as a marker for inflammation - testing for levels of CRP at time points: baseline (pre-test), 8 weeks (60 days) and 12 weeks (90 days). The final time point (i.e., 12 weeks) will serve as the post-test. It is expected that baseline CRP levels in healthy participants will decline.

Condition or disease Intervention/treatment Phase
Inflammation Dietary Supplement: NOPALEA Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 287 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Prevention
Official Title: The Effect of a Nutritional Supplement Product Containing Cactus Fruit Juice (Nopalea) on C-Reactive Protein (NOPALEA)
Study Start Date : May 2013
Actual Primary Completion Date : March 2014
Actual Study Completion Date : March 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Apricot
Supplement: Apricot Juice
Dietary Supplement: NOPALEA
Experimental: Nopalea
Supplement: Nopalea
Dietary Supplement: NOPALEA

Primary Outcome Measures :
  1. HS-CRP [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Live within traveling distance of the research center. Access to a telephone in their residence. Between 35 and 75 years of age Not currently ingesting Nopalea Not pregnant, planning to become pregnant, or nursing a child Not currently taking anti-inflammatory medications Medically stable - i.e. no recent major change in the last 3 weeks of prescription or non- prescription medication Not diagnosed with Type 1 Diabetes Not diagnosed with depression Not diagnosed with an acquired or congenital immune system deficiency

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01881178

Layout table for location information
United States, Arizona
Trivita Wellness Center
Scottsdale, Arizona, United States, 06473
Sponsors and Collaborators
Mark Mattie
Layout table for investigator information
Study Director: Mark e Mattie UBCNM

Layout table for additonal information
Responsible Party: Mark Mattie, Associate Professor, University of Bridgeport Identifier: NCT01881178     History of Changes
Other Study ID Numbers: Nopalea
First Posted: June 19, 2013    Key Record Dates
Last Update Posted: December 30, 2014
Last Verified: June 2013
Keywords provided by Mark Mattie, University of Bridgeport:
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes